CHF129.96 is the pre-market price for Novartis AG (NOVN.SW) on the SIX exchange on 03 Mar 2026, and the stock is among the most active names in Switzerland. NOVN.SW stock trades with volume at 3,727,259 shares, a relative volume of 1.16, and a market cap near CHF247.98 billion. The shares show a one-day move of -0.54 CHF or -0.41%, while the 50-day average sits at CHF117.39 and the 200-day average at CHF104.26. We summarise why liquidity is high, the valuation and technical signals, and Meyka AI’s short-term forecast for traders watching pre-market flow.

Market snapshot and pre-market flow for NOVN.SW stock

Novartis opened pre-market at CHF129.00 and is trading at CHF129.96. Volume today is 3,727,259 versus an average volume of 3,249,020. The intraday range is CHF128.54–CHF130.40 and the 52-week range is CHF81.10–CHF131.00. One clear fact: higher-than-average volume is driving NOVN.SW stock into the most-active lists on SIX this morning.

Drivers behind the activity and recent NOVN.SW news

Trading activity follows steady sector momentum in Healthcare, where drugmakers show mixed performance this week. Novartis benefits from strong product sales trends and recent pipeline updates. Reuters and Investing.com provide continuous price and news coverage for NOVN.SW; see latest trade data and company headlines for context source and historical price history source.

Fundamentals and valuation for Novartis AG (NOVN.SW)

Novartis reports EPS of 5.52 CHF and a PE ratio of 23.54. Revenue per share is 29.41 CHF and free cash flow per share is 8.76 CHF. Novartis pays a dividend near 4.49 CHF per share, implying a dividend yield around 2.69%. The balance sheet shows a debt-to-equity ratio of 0.80 and interest coverage of 15.13, supporting solvency. These metrics frame the valuation: price-to-book is 6.92 and price-to-sales is 5.66, indicating a premium relative to some peers but consistent with large-cap drugmakers.

NOVN.SW stock technicals and trading signals

Momentum indicators are bullish but near overbought. RSI stands at 72.89, MACD is 3.74 with signal 3.62, and ADX is 33.04, which signals a strong trend. The 50-day average is CHF117.39 and the 200-day average is CHF104.26, both below the current price. Bollinger band middle at CHF124.96 and ATR at 2.18 show compression after recent gains. Traders should note the performance drivers: three-month return +22.37% and year-to-date +19.78%, which explain elevated volume and momentum chasing.

Meyka AI grade and forecasts for NOVN.SW stock

Meyka AI rates NOVN.SW with a score out of 100: 78.33 / 100 — Grade B+, Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a quarterly price near CHF133.50, a monthly near CHF124.35, and a five-year scenario of CHF153.37. Compared with the current price CHF129.96, the quarterly projection implies an upside of +2.70%, while the monthly projection implies a downside of -4.29%. Forecasts are model-based projections and not guarantees. Meyka AI is an AI-powered market analysis platform used for these projections.

Price targets, scenarios and risk factors

We present scenario-based targets to frame trader expectations. Conservative target: CHF114.47 (yearly model), base target: CHF133.50 (quarterly model), and bull case: CHF153.37 (five-year model). Key risks include regulatory setbacks, generic competition for Sandoz products, and macro-driven pharma spending shifts. Key opportunities include successful launches in Innovative Medicines, strength in cash flow, and partnership revenues such as inclisiran collaborations.

Final Thoughts

NOVN.SW stock trades pre-market at CHF129.96 on SIX with heavy volume and active order flow. The picture is clear: fundamentals remain solid with EPS 5.52 CHF, PE 23.54, free cash flow yield near 5.27%, and dividend of 4.49 CHF supporting income investors. Technicals show strength but elevated RSI warns of short-term pullbacks. Meyka AI’s forecast model projects a quarterly price of CHF133.50, implying a modest upside of +2.70% versus the current quote. Our grade — 78.33/100 (B+, BUY) — balances strong profitability and cash generation against valuation premiums and sector risks. Traders and investors should weigh short-term momentum against longer-term scenario targets and use stop limits for pre-market entries. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.